Ocular Therapeutix Aligns with FDA on AXPAXLI NDA Submission for Wet AMD

Event summary

  • Ocular Therapeutix plans to submit AXPAXLI NDA for wet AMD in Q4 2026, based on SOL-1 efficacy and safety data plus interim SOL-R safety data.
  • SOL-R efficacy data is no longer part of the NDA submission plan; the trial will now focus on long-term strategic objectives.
  • Ocular will evaluate AXPAXLI's superiority over aflibercept (8mg) Q6M at Week 96 as a key secondary endpoint of the SOL-R trial.
  • The company will streamline its diabetic retinopathy program to prioritize a single Phase 3 trial, HELIOS-3, evaluating Q12M dosing of AXPAXLI.

The big picture

Ocular Therapeutix's strategic shift to prioritize AXPAXLI's NDA submission reflects a broader industry trend toward regulatory efficiency and product differentiation in the wet AMD space. The company's alignment with the FDA on the 505(b)(2) pathway and focus on long-term strategic objectives for AXPAXLI highlight its commitment to bringing a potentially best-in-class therapy to market. The streamlining of the diabetic retinopathy program underscores the growing emphasis on once-yearly treatment paradigms in retinal disease.

What we're watching

Regulatory Pathway
Whether the FDA's alignment on the 505(b)(2) pathway will accelerate AXPAXLI's review timeline by up to 60 days.
Clinical Trial Outcomes
The pace at which SOL-R trial data will establish AXPAXLI as a best-in-disease agent for wet AMD.
Market Adoption
How the streamlined diabetic retinopathy program will impact AXPAXLI's commercial potential in diabetic retinal disease.